PCI extends industry leading position for product security for global medicines with significant serialisation and anticounterfeiting technology investment
Biopharmaceutical services provider PCI Pharma Services is celebrating a milestone in the protection of global drug products with the installation of its 80th serialisation line, further extending its advanced position across its global supply network. Considered an industry leader in product security for global medicines through advanced serialisation and anticounterfeiting technologies, PCI continues to invest heavily in services advancing the commercialisation of therapies destined to domestic and global markets, supporting medicines destined to more than 100 countries around the world.
PCI’s preparedness for global product security requirements has spanned more than seven years, with support for products meeting the US Drug Supply Chain Security Act (DSCSA), European Union’s Falsified Medicines Directive (FMD), as well as in-country requirements in emerging markets including South Korea, Russia, China, Brazil, Saudi Arabia and Turkey among others. With PCI’s expert architecture, clients enjoy singular connectivity to access the entirety of PCI’s extensive global supply network in delivering Serialised medicines with integrated overt and covert Anticounterfeiting protection features.
We leveraged our knowledge and looked to implement a strategy that focused on the industry leading experience for our customers
"It’s been a long journey," notes Brad Payne, PCI’s Senior Vice President of Global Operations. "At the earliest stages of our preparedness, we leveraged our knowledge and looked to implement a strategy that focused on the industry leading experience for our customers, pairing the best technologies while maximising ease of use, all with an eye towards allowing for scalability – knowing that at some point we would see the market finally reach maturity in terms of firm governmental requirements and a common framework."
In addition to industry leading investment in serialisation and anticounterfeiting capability, PCI has added new facilities in San Diego, California and Dublin, Ireland, as well as Melbourne, Australia in support of global drug supply for both commercial medicines as well as investigational clinical trial medicines. With an integrated molecule-to-market service offering including drug development, scalable drug manufacture, clinical trial packaging and labelling, storage and distribution, as well as commercial packaging services, PCI has now expanded to eight sites comprised of 20 facilities, supported by more than 3,500 associates.